Windtree Therapeutics Inc
NASDAQ:WINT
Windtree Therapeutics Inc
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company, which engages in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 33 full-time employees. The Company’s development programs are primarily focused on the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Its Cardiovascular Program’s products candidates include Istaroxime, Oral SERCA2a Activators and Rostafuroxin. Its Pulmonary Program’s product candidates include Lyophilized KL4 Surfactant and AEROSURF (aerosolized KL4 surfactant based on ADS technology). The Company’s lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure (AHF) with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and is under phase II clinical trials.
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company, which engages in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 33 full-time employees. The Company’s development programs are primarily focused on the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Its Cardiovascular Program’s products candidates include Istaroxime, Oral SERCA2a Activators and Rostafuroxin. Its Pulmonary Program’s product candidates include Lyophilized KL4 Surfactant and AEROSURF (aerosolized KL4 surfactant based on ADS technology). The Company’s lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure (AHF) with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and is under phase II clinical trials.
